medical decision support medical decision support
Sign In

Use of Stage and p63 Immunostaining to Predict Prognosis for a Patient with an Adenoid Cystic Carcinoma Arising in a Salivary Gland

Description

Ramer et al used p63 immunostaining and tumor stage to predict prognosis for a patient with an adenoid cystic carcinoma arising in a salivary gland. These findings can help to identify a patient who may benefit from more aggressive management. The authors are from Mount Sinai School of Medicine, Tisch Cancer Institute, and Rambam Medical Center (Haifa).


 

Parameters:

(1) tumor stage (Stage I, II, III or IV)

(2) percent of tumor cells showing nuclear immunostaining for p63

Parameter

Finding

Points

tumor stage

low (Stage I or II)

0

 

high (Stage III or IV)

1

percent nuclei positive for p63

< 35%

0

 

>= 35%

1

 

where:

• Criteria for low and high stage was not found in the text. The above separation is based on the numbers shown for each stage on page 79 (right column top) and in Figure 5 page 81.

 

tumor score =

= (points for stage) + (points for p63 staining)

 

Interpreation:

• minimum score: 0

• maximum score: 2

• The higher the score the worse the prognosis.

 

Tumor Score

Group

10 Year Survival

0

A

100%

1

B

about 50%

2

C

0%

 


To read more or access our algorithms and calculators, please log in or register.

Specialty